Condition
Post-COVID ME/CFS
Total Trials
5
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Completed3
Not Yet Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06118138CompletedPrimary
Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS
NCT05697640Phase 2Active Not RecruitingPrimary
Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome
NCT05710770Not ApplicableCompleted
Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS
NCT05629988CompletedPrimary
Repeat Immunoadsorption Post Covid ME/CFS
NCT06739720Phase 2Not Yet Recruiting
RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue
Showing all 5 trials